Clinical Trial

qDSA Blood Flow Measurement in Patients Undergoing TAE of the Liver

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this research is to evaluate a new technique, quantitative digital subtraction angiography (qDSA), to measure blood flow during liver embolization procedures. Liver embolization is a way of treating liver tumors by blocking blood flow to it. The qDSA technique could help doctors ensure the blood flow to the tumor is decreased by the right amount by calculating blood flow before, during, and after the procedure. Up to 20 participants will be enrolled for 1 study visit and data collection for up to 6 months.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-06; most recent amendment 2026-03-25.
Trial Details
NCT Number NCT06971991
Lead Sponsor University of Wisconsin, Madison
Collaborators: Siemens Medical Solutions
Conditions Transarterial Embolism, Transarterial Chemoembolization, Radioembolization
Enrollment 20 participants
Start Date 2025-03-13
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-30